NXP Semiconductors N.V. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? NXP Semiconductors N.V. Common Stock trades at $218.47 (market cap $55.69B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: NXP Semiconductors N.V. Common Stock is far larger — about 38.4× uniQure N.V. Ordinary Shares's market cap, and NXP Semiconductors N.V. Common Stock pays a 1.84% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold NXP Semiconductors N.V. Common Stock for 5 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NXPI | QURE | |
|---|---|---|
Market Cap | $55.69B | $1.45B |
Volume | 4,397,771 | 3,323,243 |
Sector | Technology | Health |
52-Week High | $332.67 | $70.59 |
52-Week Low | $184.19 | $9.03 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $63.80B | $707.46M |
Dividend Yield | 1.84% | — |
Signals from Pluang's Aura AI — not financial advice
NXP Semiconductors (NXPI) trades at $226.32, up 0.49% with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue grew to $12.27B in 2025 with a robust 22.56% net margin, while analysts maintain a 65% buy rating with a $282.88 consensus target. Recent news highlights executive stock sales and focus on physical AI leadership.
NXPI offers growth potential driven by earnings beats and strategic positioning in semiconductors, but faces near-term technical pressure and competitive risks. The stock trades below analyst targets, suggesting upside if fundamentals hold. Key risks include market volatility and execution challenges in a cyclical industry.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
NXP Semiconductors designs semiconductor solutions for embedded applications. Its products serve automotive, industrial and IoT, mobile, and communications-infrastructure markets.
Read more on NXPI →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →